Cylene Pharmaceutical Raises $26.3M

San Diego-based Cylene Pharmaceuticals, a biotech company focused on the discovery and development of oncology drugs, said that it has raised $26.3M. The Series B funding was led by Coastview Capital. Cylene said that the funding will help advance its lead product for treatment of cancer. New investors included BioVentures Investors, Mitsui & Co. Venture Partners, Morningside Venture Investments, TDL Investors, William Harris Investors, Lakeview Capital, and the Viterbi Group. Existing shareholders Sanderling Ventures, Novartis BioVentures, Research Corporation Technologies, and IngleWood Ventures also participated. More information »